Vascular endothelial growth factor-transfected adipose-derived stromal cells enhance bone regeneration and neovascularization from bone marrow stromal cells.
Kang ML., Kim JE., Im GI.
Animal Study, published in J Tissue Eng Regen Med (2017) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Tissue Eng Regen Med (2017)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 28198165
- DOI
- 10.1002/term.2247
- Citations
- 22
Abstract (original English)
Vascular endothelial growth factor (VEGF)-transfected adipose-derived stromal cells (ADSCs VEGF ) were devised to promote bone regeneration and neovascularization of bone marrow stromal cells (BMSCs). ADSCs VEGF were added to BMSCs and cocultured in variable proportions. ADSCs VEGF alone or ADSCs VEGF with BMSCs (BMSCs:ADSCs VEGF ratio of 1:0.025-0.5) induced significantly greater tube formation in human umbilical vein endothelial cells than untransfected ADSCs. The cocultures of BMSCs and ADSCs VEGF at ratios of 1: 0.025-0.1 showed significantly greater osteogenic differentiation and mineralization than BMSCs alone in vitro. Osteogenic markers COL1A1, OCN and BSP were most effectively induced at the BMSC: ADSC VEGF ratio of 1:0.05. Of angiogenesis-related genes, upregulation of cathepsin Z and downregulation of early growth response 1 were observed while two osteogenesis-related genes, osteoactivin and tetranectin, were upregulated in BMSCs/ADSCs VEGF compared to BMSCs/ADSCs. When critical size calvarial defects in rats were implanted with mixture of BMSCs and ADSCs VEGF along with hydroxyapatite/β-tricalcium phosphate granules, BMSCs and ADSCs VEGF at the ratio of 1:0.05 showed better bone regeneration that BMSCs alone. The cotransplantation of ADSCs VEGF with BMSCs significantly increased neovascularization on the regenerated bone of the repaired defect than BMSCs alone. In
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.